Minimally Invasive Local Treatments for Bone and Pulmonary Metastases

Table 3

Summary of clinical trials evaluating radiopharmaceuticals.

Radionuclide	Cancer	Trial	Pain response	Survival
Phosphorous-32 (^32P)
Nair [29]	Breast, prostate, lung, and other	^32P versus ^89Sr	>50% reduction in pain in 93.3% of pts with ^89Sr and 87.5% in ^32P	Not reported
Strontium-89 (^89Sr)
Smeland et al. [30]	Prostate, breast, and other	RT + ^89Sr versus RT + placebo	30% versus 20% (NS)	27 weeks versus 34 weeks; (𝑃=0.6)
Porter and McEwan [31]	Prostate	RT + ^89Sr versus RT + placebo	30–60% (complete response)
Lewington et al. [32]	Prostate	^89Sr versus placebo	Statistically significant decrease in pain
Samarium-153 (^153Sm)
Serafini et al. [33]	Prostate, breast, lung, and other	^153Sm versus placebo	72%	Not reported
Collins et al. [34]	Prostate	Phase I/II for ^153Sm	76%
Resche et al. [35]	Prostate, breast, lung, and other	^153Sm 0.5 mCi/kg versus ^153Sm 1.0 mCi/kg	55% versus 70% at week 4
Radium-223 (^223Ra)
Parker et al. [39]	Prostate	^223Ra versus placebo	Median time to first symptomatic skeletal event: 15.6 mo.	14.9 mo. versus 11.3 mo.; (𝑃<0.001)